Table 4.
Comparison of the clinical pathological features and patient prognosis in the TMUB1/STAT1 under-expression and over-expression.
| Biological characteristics | TMUB1high/STAT1hhigh | TMUB1high/STAT1low | TMUB1low/STAT1high | TMUB1low/STAT1low | P value |
|---|---|---|---|---|---|
| Numbers of patient | 58 | 21 | 19 | 34 | |
| Mean tumor size (cm) | 4.7±2.0 | 6.7±3.0 | 5.3±2.7 | 7.8±4.4 | <0.001 |
| Numbers of tumors ≥2 | 7 (5.3%) | 4 (3.0%) | 8 (6.1%) | 11 (8.3%) | 0.021 |
| TNM stage | 0.016 | ||||
| Stage I | 49 (37.1%) | 15 (11.3%) | 10 (7.6%) | 20 (15.2%) | |
| Stage II | 7 (5.3%) | 5 (3.8%) | 6 (4.5%) | 5 (3.8%) | |
| Stage III | 1 (0.8%) | 1 (0.8%) | 3 (2.3%) | 6 (4.5%) | |
| Stage IV | 1 (0.8%) | 1 (0.8%) | 0 (0.0%) | 3 (2.3%) | |
| HCC differentiation | 0.002 | ||||
| WD | 20 (15.2%) | 2 (1.5%) | 2 (1.5%) | 6 (4.5%) | |
| MD | 30 (22.7%) | 12 (9.1%) | 13 (9.8%) | 11 (8.3%) | |
| PD | 8 (6.1%) | 7 (5.3%) | 4 (3.0%) | 17 (12.9%) | |
| Lymph node metastasis | 1 (0.8%) | 0 (0.0%) | 0 (0.0%) | 1 (0.8%) | >0.05 |
| Vascular invasion | 6 (4.5%) | 6 (4.5%) | 2 (1.5%) | 6 (4.5%) | >0.05 |
| Extrahepatic metastasis | 1 (0.8%) | 0 (0.0%) | 1 (0.8%) | 2 (1.5%) | >0.05 |
| Postoperative recurrence | 35 (26.5%) | 6 (4.5%) | 14 (10.6%) | 26 (19.7%) | 0.003 |
| Cancer related death | 24 (18.2%) | 13 (9.8%) | 13 (9.8%) | 23 (17.4%) | 0.030 |
STAT1 – signal transducer and activator of transcription 1.